Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 3/20 | 0.64 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.49 |
| ▸ | TUBB | P07437 | 3/20 | 0.49 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.49 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.49 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.49 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.49 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.49 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.49 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.49 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.49 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.49 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.49 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.49 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.49 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.46 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL520554 | 0.88 | QDPR (0.68) | QDPRTGFBR1ACVR1KCNH2HTR1A | |
| SCHEMBL29517150 | 0.88 | QDPR (0.68) | QDPRTGFBR1ACVR1KCNH2HTR1A | |
| SCHEMBL28328504 | 0.83 | DRD2 (0.47) | QDPRTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL3502613 | 0.82 | QDPR (0.48) | QDPRTGFBR1ACVR1KCNH2HTR1D | |
| SCHEMBL1264565 | 0.82 | TUBB4A (0.53) | QDPRTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL30778335 | 0.82 | QDPR (0.59) | QDPRHTR1DHTR1BTLR9TLR7 | |
| SCHEMBL15157280 | 0.82 | QDPR (0.59) | QDPRHTR1DHTR1BTLR9TLR7 | |
| SCHEMBL23605276 | 0.81 | QDPR (0.64) | QDPRTGFBR1ACVR1KCNH2HTR1A | |
| SCHEMBL24992436 | 0.81 | QDPR (0.64) | QDPRTGFBR1ACVR1KCNH2HTR1A | |
| SCHEMBL23605689 | 0.81 | QDPR (0.64) | QDPRTGFBR1ACVR1KCNH2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212147-A1 | ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-07-06 | — | — | US | disclosed |
| US-20230212147-A1 | ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-07-06 | — | — | US | disclosed |
| WO-2023011610-A1 | BENZODIOXANE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 南京红云生物科技有限公司 | 2023-02-09 | — | — | WO | disclosed |
| WO-2021249324-A1 | ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 南京红云生物科技有限公司 | 2021-12-16 | — | — | WO | disclosed |
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212147-A1 | ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | WEE1, EGFR, WEE2 | QDPR 602/4885TUBB4A 4012/4885TUBB 3452/4885 |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | QDPR 807/4885TUBB4A 1509/4885TUBB 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.